We encourage the European Commission and HTA Coordination Group to work closely with Health Technology Developers to ensure the processes and methodologies outlined in the implementing acts will be fit for purpose and provide a clear and transparent, workable, and predictable process. The HTAR should ensure the use of state-of-the-art scientific methodology, including appropriate handling of evidence uncertainty, reflecting specifics of the context of disease and medicine development.
Anouk De Vroey, Head of Government Affairs & Policy at Johnson & Johnson EMEA, pharma & vaccines, set out to meet experts and explore as well as illustrate how IP facilitates development for different actors at many stages of the development process. Her conversations are captured in a series of videos produced for our Evolution of Healthcare Campaign[7] in collaboration with POLITICO Studio.
In a first conversation, Anouk discusses with Dirk De Smaele, Global Head of Chemical Pharmaceutical Development & Supply. They explain how exactly IP contributes to providing options for patients and how it takes costs out of the health system.
Together with Prof. Dr Thomas De Beer, professor in Process Analytical Technology at the Faculty of Pharmaceutical Sciences at Ghent University, Anouk sheds light on the vital role of IP for academic research and how it unlocks the ability for universities and institutes to collaborate as well as to reach patients through scaling of discoveries and new technologies.